These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30893088)

  • 41. Epeleuton, a novel synthetic ω-3 fatty acid, reduces hypoxia/ reperfusion stress in a mouse model of sickle cell disease.
    Mattè A; Federti E; Recchiuti A; Hamza M; Ferri G; Riccardi V; Ceolan J; Passarini A; Mazzi F; Siciliano A; Bhatt DL; Coughlan D; Climax J; Gremese E; Brugnara C; De Franceschi L
    Haematologica; 2024 Jun; 109(6):1918-1932. PubMed ID: 38105727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sickle cell disease: a chronic inflammatory condition.
    Chies JA; Nardi NB
    Med Hypotheses; 2001 Jul; 57(1):46-50. PubMed ID: 11421623
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Daily pain in adults with sickle cell disease-a different perspective.
    van Tuijn CF; Sins JW; Fijnvandraat K; Biemond BJ
    Am J Hematol; 2017 Feb; 92(2):179-186. PubMed ID: 27880985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain.
    Hebbel RP
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):181-98. PubMed ID: 24589261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Daily home opioid use in adults with sickle cell disease: The PiSCES project.
    Smith WR; McClish DK; Dahman BA; Levenson JL; Aisiku IP; de A Citero V; Bovbjerg VE; Roberts JD; Penberthy LT; Roseff SD
    J Opioid Manag; 2015; 11(3):243-53. PubMed ID: 25985809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of vasoocclusive pain events in sickle cell disease.
    Ellison AM; Shaw K
    Pediatr Emerg Care; 2007 Nov; 23(11):832-8; quiz 838-41. PubMed ID: 18007218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.
    Nobrega R; Sheehy KA; Lippold C; Rice AL; Finkel JC; Quezado ZMN
    Pediatr Res; 2018 Feb; 83(2):445-454. PubMed ID: 28902183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate.
    Belcher JD; Chen C; Nguyen J; Zhang P; Abdulla F; Nguyen P; Killeen T; Xu P; O'Sullivan G; Nath KA; Vercellotti GM
    Antioxid Redox Signal; 2017 May; 26(14):748-762. PubMed ID: 26914345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series.
    Palm N; Floroff C; Hassig TB; Boylan A; Kanter J
    J Pain Palliat Care Pharmacother; 2018 Mar; 32(1):20-26. PubMed ID: 29791238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of Sickle Cell Pain Using Pregabalin: A Pilot Study.
    Schlaeger JM; Molokie RE; Yao Y; Suarez ML; Golembiewski J; Wilkie DJ; Votta-Velis G
    Pain Manag Nurs; 2017 Dec; 18(6):391-400. PubMed ID: 28843636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sickle cell disease, vasculopathy, and therapeutics.
    Kassim AA; DeBaun MR
    Annu Rev Med; 2013; 64():451-66. PubMed ID: 23190149
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting inflammatory components in neuropathic pain: The analgesic effect of thymulin related peptide.
    Safieh-Garabedian B; Nomikos M; Saadé N
    Neurosci Lett; 2019 May; 702():61-65. PubMed ID: 30503917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Psychosocial and pharmacological management of pain in pediatric sickle cell disease.
    Hildenbrand AK; Nicholls EG; Daly BP; Marsac ML; Tarazi R; Deepti R
    Postgrad Med; 2014 Mar; 126(2):123-33. PubMed ID: 24685976
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frequently asked questions by hospitalists managing pain in adults with sickle cell disease.
    Smith WR; Jordan LB; Hassell KL
    J Hosp Med; 2011 May; 6(5):297-303. PubMed ID: 21661104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Carbon-fiber microelectrode amperometry reveals sickle-cell-induced inflammation and chronic morphine effects on single mast cells.
    Manning BM; Hebbel RP; Gupta K; Haynes CL
    ACS Chem Biol; 2012 Mar; 7(3):543-51. PubMed ID: 22217155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of a dedicated day hospital for management of acute sickle cell pain.
    Adewoye AH; Nolan V; McMahon L; Ma Q; Steinberg MH
    Haematologica; 2007 Jun; 92(6):854-5. PubMed ID: 17550862
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pain syndromes in sickle cell disease: an update.
    Niscola P; Sorrentino F; Scaramucci L; de Fabritiis P; Cianciulli P
    Pain Med; 2009 Apr; 10(3):470-80. PubMed ID: 19416438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of vaso-occlusive episodes in the day hospital decreases admissions in children with sickle cell disease.
    Karkoska K; Appiah-Kubi A; Rocker J; Stoffels G; Aygun B
    Br J Haematol; 2019 Sep; 186(6):855-860. PubMed ID: 31148158
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.
    De Franceschi L; Mura P; Schweiger V; Vencato E; Quaglia FM; Delmonte L; Evangelista M; Polati E; Olivieri O; Finco G
    Pain Pract; 2016 Jul; 16(6):680-7. PubMed ID: 26009799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inflammation in sickle cell disease.
    Conran N; Belcher JD
    Clin Hemorheol Microcirc; 2018; 68(2-3):263-299. PubMed ID: 29614637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.